Duska and DSM Pharmaceuticals partner to manufacture PSVT drug product
Duska is in the process of modifying the proposed design of the Phase III clinical trial in accordance with the FDA’s comments and plans to submit a revised
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
In each Phase II study, VIA-2291 inhibited production of leukotrienes, proposed mediators of vascular inflammation. VIA-2291 was generally well-tolerated, the company said. According to the company, the first